Targeted systemic dendrimer delivery of CSF‐1R inhibitor to tumor‐associated macrophages improves outcomes in orthotopic glioblastoma

Glioblastoma is the most common and aggressive form of primary brain cancer, with median survival of 16–20 months and a 5‐year survival rates of

Saved in:
Bibliographic Details
Published in:Bioengineering & translational medicine 2021-05, Vol.6 (2), p.e10205-n/a
Main Authors: Liaw, Kevin, Reddy, Rajsekhar, Sharma, Anjali, Li, Jiangyu, Chang, Michelle, Sharma, Rishi, Salazar, Sebastian, Kannan, Sujatha, Kannan, Rangaramanujam M.
Format: Article
Language:English
Subjects:
Brain
Brain cancer
Cancer therapies
Chromatography
Conjugation
Cytokines
dendrimer
Dendrimers
Drug dosages
Experiments
glioblastoma
Immunotherapy
Inhibitors
Lymphocytes
Macrophages
Medical prognosis
Metastasis
Phosphorylation
Research Report
Research Reports
Survival
Sustained release
systemic
targeted delivery
Toxicity
Tumors
tumor‐associated macrophage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma is the most common and aggressive form of primary brain cancer, with median survival of 16–20 months and a 5‐year survival rates of
ISSN:2380-6761
2380-6761
DOI:10.1002/btm2.10205